Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 2/20 | 0.37 |
| ▸ | AURKA | O14965 | 2/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | PRKACA | P17612 | 1/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | MARK3 | P27448 | 1/20 | 0.37 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.37 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.37 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8856393 | 0.59 | CHEK1 (0.47) | CHEK1AURKALRRK2PDPK1CHEK2 | |
| SCHEMBL31268389 | 0.56 | LRRK2 (0.44) | CHEK1AURKALRRK2PDPK1CHEK2 | |
| SCHEMBL2316376 | 0.55 | CHEK1 (0.42) | CHEK1AURKALRRK2PDPK1CHEK2 | |
| SCHEMBL31029494 | 0.55 | LRRK2 (0.39) | CHEK1AURKALRRK2PDPK1CHEK2 | |
| Dimethyladenine SCHEMBL29349831 | 0.54 | LRRK2 (1.00) | CHEK1AURKALRRK2PDPK1CHEK2 | |
| SCHEMBL18519961 | 0.53 | CHEK1 (0.41) | CHEK1AURKALRRK2PDPK1CHEK2 | |
| SCHEMBL15086982 | 0.53 | JAK3 (0.62) | CHEK1AURKA | |
| SCHEMBL31685448 | 0.53 | CHEK1 (0.38) | CHEK1AURKALRRK2PDPK1CHEK2 | |
| Dimethyladenine SCHEMBL11157548 | 0.53 | PDPK1 (0.96) | CHEK1AURKALRRK2PDPK1CHEK2 | |
| SCHEMBL13717980 | 0.53 | CHEK1 (1.00) | CHEK1AURKALRRK2PDPK1CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5641763-A | N-phosphonylmethoxyalkyl derivatives of pyrimdine and purine bases and a therapeutical composition therefrom with antiviral activity | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1997-06-24 | — | — | US | claimed |
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. | 2013-10-31 | — | — | US | disclosed |
| US-8497278-B2 | Imidazo[1,2-a]pyridine compounds | SUNOVION PHARMACEUTICALS INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. (US) | 2011-07-07 | — | — | US | disclosed |
| EP-2300470-A2 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS GABA-A RECEPTOR MODULATORS | Sepracor Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009143156-A2 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SEPRACOR INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-5631259-A | PURINE BASE DERIVATIVES FOR NUCLEOSIDES | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-05-20 | — | — | US | disclosed |
| WO-1995031459-A1 | MORPHOLINO-SUBUNIT COMBINATORIAL LIBRARY AND METHOD | ANTIVIRALS INC. (US) | 1995-11-23 | — | — | WO | disclosed |
| EP-0521463-A2 | Substituted cyclic cycloalkyltriols, process, intermediates for their preparation and their use as antiviral and antiparasitic agents | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-01-07 | — | — | EP | disclosed |
| US-3935184-A | Synthetic polyoxin type nucleosides | SYNTEX (U.S.A.) INC. (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | CHEK1 3718/4885AURKA 1010/4885LRRK2 4215/4885 |
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | CHEK1 3718/4885AURKA 1010/4885LRRK2 4215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.